Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
inpefa sotagliflozin
4
inpefa
1
Similar Publications
Inpefa (sotagliflozin).
WMJ
April 2024
Medical College of Wisconsin School of Pharmacy, Milwaukee, Wisconsin,
Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure.
Ann Pharmacother
September 2024
Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, CT, USA.
Article Synopsis
- Sotagliflozin Overview
- : Sotagliflozin is the first drug approved that inhibits both sodium-glucose cotransporter 1 (SGLT1) and SGLT2, primarily aimed at managing heart failure (HF) in patients with type 2 diabetes mellitus (T2DM).
- Clinical Evidence
- : Phase 3 trials (SOLOIST-WHF and SCORED) showed that sotagliflozin significantly reduced cardiovascular and heart failure events compared to a placebo, indicating its potential efficacy in high-risk patients.
- Patient Care Implications
- : Despite its approval, established SGLT2 inhibitors like dapagliflozin and empagliflozin have
Letter to the Editor: Latest FDA Approved Drug Sotagliflozin (Inpefa): A Glance at its Prospectives for Heart Failure.
Curr Probl Cardiol
November 2023
Department of Cardiology, Shaikh Khalifa Bin Zayed Al-Nahyan Medical and Dental College, Lahore, Punjab, Pakistan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!